Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review

References

• SieguelRLMillerKDJemalACancer statistics, 2017CA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• TillyHGaulardPLepageEPrimary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcomeBlood1997909372737349345059
   PubMed Web of Science ®Google Scholar
• SteinHFossHDMarafiotiMCD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical featuresBlood200096123681369511090048
   PubMed Web of Science ®Google Scholar
• SenterPDSieversELThe discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphomaNat Biotechnol201230763163722781692
   PubMed Web of Science ®Google Scholar
• YiJHKimSJKimWSBrentuximab vedotin: clinical updates and practical guidanceBlood Res201752424325329333400
   PubMed Web of Science ®Google Scholar
• BartlettNLEmerging role of novel therapies in Hodgkin lymphoma: proceed with cautionHematology Am Soc Hematol Educ Program20172017131732329222273
   PubMed Web of Science ®Google Scholar
• AraiSFanaleMDeVosSDefining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplantLeuk Lymphoma201354112531253323617324
   PubMed Web of Science ®Google Scholar
• CrumpMManagement of Hodgkin lymphoma in relapse after autologous stem cell transplantHematology Am Soc Hematol Educ Program200832633319074105
   PubMedGoogle Scholar
• YounesAGopalAKSmithSEResults of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphomaJ Clin Oncol201230182183218922454421
   PubMed Web of Science ®Google Scholar
• ChenRGopalAKSmithSEFive-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphomaBlood2016128121562156627432875
   PubMed Web of Science ®Google Scholar
• MoskowitzCHNademaneeAMassziTAETHERA Study GroupBrentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trialLancet201538599801853186225796459
   PubMed Web of Science ®Google Scholar
• SweetenhamJWalewskiJNademaneeAPUpdated efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapseBlood20151263172
   Web of Science ®Google Scholar
• ChenRPalmerJMMartinPResults of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphomaBiol Blood Marrow Transplant201521122136214026211987
   PubMed Web of Science ®Google Scholar
• MichalletASGuillerminYDeauBSequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphomaHaematologica20151007e269e27125840598
   PubMed Web of Science ®Google Scholar
• MoskowitzAJSchoderHYahalomJPET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 studyLancet Oncol201516328429225683846
   PubMed Web of Science ®Google Scholar
• CassadayRDFrommJCowanAJSafety and activity of brentuximab vedotin plus ifosfamide, carboplatin, and etposide (ICE) for relapsed/refractory classical Hodgkin lymphoma: initial results of a phase I/II trialBlood2016128183427465916
   PubMed Web of Science ®Google Scholar
• LaCasceASBociekGSawasABrentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphomaBlood20151263982
   Web of Science ®Google Scholar
• Garcia-SanzRSuredaAGonzalezAPBrentuximab vedotin plus ESHAP (BESHAP) is a highly effective combination for inducing remission in refractory and relapsed Hodgkin lymphoma patients prior to autologous stem cell transplant: a trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)Blood20161281109
   Web of Science ®Google Scholar
• HerreraAFBartlettNLRamchandrenRPreliminary results from a phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphomaBlood20161281105
   Web of Science ®Google Scholar
• DiefenbachCSHongFDavidKAA phase I study with an expansion cohort of the combination of Ipilimumab an nivolumab and brentuximab vedotin in patients with relapse/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)Blood20161281106
   Web of Science ®Google Scholar
• BartlettNLChenRFanaleMARetretament with brentuximab vedotin in patients with CD30-positive hematologic malignanciesJ Hematol Oncol201471824387695
   PubMed Web of Science ®Google Scholar
• Forero-TorresAHolkovaBGoldschmidtJPhase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and olderBlood2015126262798280426377597
   PubMed Web of Science ®Google Scholar
• GibbAPirrieSLintonKResults of phase II study of brentuximab vedotin in the first line treatment of Hodgkin lymphoma patients considered unsuitable for standard chemotherapy (BREVITY)Hematol Oncol201735Suppl 2808128591413
   PubMed Web of Science ®Google Scholar
• GallaminiABijouFViottiJBrentuximab-vedotin and benda-mustine is a feasible and effective drugs combination as first-line treatment of Hodgkin lymphoma in the elderly (HALO TRIAL)Hematol Oncol201735Suppl 2170
   Google Scholar
• FriedbergJWForero-TorresABordoniREFrontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HLBlood2017130262829283729038340
   PubMed Web of Science ®Google Scholar
• YounesAConnorsJMParkSIBrentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation studyLancet Oncol201314131348135624239220
   PubMed Web of Science ®Google Scholar
• ConnorsJMAnsellSFanaleMAParkSIYounesAFive-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphomaBlood2017130111375137728733323
   PubMed Web of Science ®Google Scholar
• KumarACasuloCYahalomJBrentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphomaBlood2016128111458146427458003
   PubMed Web of Science ®Google Scholar
• ConnorsJMJurczakWStrausDJBrentuximab vedotin with chemotherapy for stage III or IV hodgkin’s lymphomaN Engl J Med2018378433134429224502
   PubMed Web of Science ®Google Scholar
• BorchmannPEichenauerDAPluetschowATargeted BEACOPP variants in patients in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: final analysis of a randomized phase II studyBlood2015126580
   Web of Science ®Google Scholar
• TsuyamaNSakamotoKSakataSDobashiATakeuchiKAnaplastic large cell lymphoma: pathology, genetics, and clinical aspectsJ Clin Exp Hematop201757312014229279550
   PubMed Web of Science ®Google Scholar
• SavageKJHarrisNLVoseJMALK anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma ProjectBlood2008111125496550418385450
   PubMed Web of Science ®Google Scholar
• SmithSMBurnsLJvan BesienKHematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphomaJ Clin Oncol201331253100310923897963
   PubMed Web of Science ®Google Scholar
• MorelABrièreJLamantLLong-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: a LYSA/SFGM-TC studyEur J Cancer20178314615328735072
   PubMed Web of Science ®Google Scholar
• YounesABartlettNLLeonardJPBrentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomasN Engl J Med2010363191812182121047225
   PubMed Web of Science ®Google Scholar
• ProBAdvaniRBricePBrentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II studyJ Clin Oncol201230182190219622614995
   PubMed Web of Science ®Google Scholar
• ProBAdvaniRBricePFive-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphomaBlood2017130252709271728974506
   PubMed Web of Science ®Google Scholar
• BroccoliAPellegriniCDi RoccoAItalian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphomaHaematologica2017102111931193528775121
   PubMed Web of Science ®Google Scholar
• FerreriAJGoviSPileriSASavageKJAnaplastic large cell lymphoma, ALK-negativeCrit Rev Oncol Hematol201385220621522789917
   PubMed Web of Science ®Google Scholar
• ChenXSomaLAFrommJRTargeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotinOnco Targets Ther20137455624379682
   PubMed Web of Science ®Google Scholar
• FanaleMAHorwitzSMForero-TorresAFive-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomasBlood201813192120212429507077
   PubMed Web of Science ®Google Scholar
• ZinzaniPLSasseSRadfordJShonukanOBonthapallyVExperience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: review of the literatureCrit Rev Oncol Hematol201595335936925964164
   PubMed Web of Science ®Google Scholar
• PerrotAMonjanelHBouabdallahRLymphoma Study Association (LYSA)Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient ProgramHaematologica2016101446647326768687
   PubMed Web of Science ®Google Scholar
• ChenRAlliboneSBartlettNLPatient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphomaOnco Targets Ther201692027203427103829
   PubMed Web of Science ®Google Scholar
• RamseySDNademaneeAMassziTQuality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphomaBr J Haematol2016175586086727649689
   PubMed Web of Science ®Google Scholar
• DonatoEMFernández-ZarzosoMDe La RubiaJImmunotherapy for the treatment of Hodgkin lymphomaExpert Rev Hematol201710541742328359170
   PubMed Web of Science ®Google Scholar